NovoCure Ltd (NVCR)
NASDAQ:NVCR
Want to see NVCR full AI Analyst Report?
NVCR Stock Chart & Stats
$12.83
-$0.69(-2.38%)
At close: 4:00 PM EST
$12.83
-$0.69(-2.38%)
Day’s Range― - ―
52-Week Range$9.82 - $20.06
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.12M
Market Cap
$1.42B
Enterprise Value$1.61B
Total Cash (Recent Filing)$457.52M
Total Debt (Recent Filing)$290.00M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Apr 30, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding113,794,395
10 Day Avg. Volume1,146,394
30 Day Avg. Volume1,119,958
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market Cap1.13
Enterprise Value/Revenue2.45
Enterprise Value/Gross Profit3.29
Enterprise Value/Ebitda-12.25
Forecast
1Y Price Target
$27.40Price Target Upside113.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$694.69M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPANOVA-4 Phase 2 meeting its disease control rate primary endpoint indicates the Optune Pax combination demonstrated clinical activity in metastatic pancreatic cancer, supporting further clinical development.
Commercial Strategy And Financial OutlookLeveraging existing commercial and field teams for the pancreatic launch reduces the need for additional sales hires and limits upfront capital requirements, aiding the path toward adjusted EBITDA break-even.
Regulatory ApprovalFDA approval for Optune Pax in locally advanced pancreatic cancer, supported by randomized trial data showing a survival benefit, strengthens the therapy's credibility with clinicians and payers.
Bears Say
Clinical Efficacy UncertaintyObjective response rate and median overall survival not showing a clear advantage versus historical control raises uncertainty about the regimen's likelihood of succeeding in a confirmatory Phase 3 study.
Competitive Landscape And Commercial FocusA crowded metastatic pancreatic cancer development environment with newer targeted therapies, combined with scaled-back commercial efforts for the non-small cell lung cancer indication, may pressure market share and near-term sales growth.
Reimbursement And Billing RiskRevocation of Medicare billing privileges and the current inability to bill Medicare or Medicare Advantage could delay material revenue recognition until billing privileges are reinstated and reimbursement codes are secured.
NovoCure News
NVCR FAQ
What was NovoCure Ltd’s price range in the past 12 months?
NovoCure Ltd lowest stock price was $9.82 and its highest was $20.06 in the past 12 months.
What is NovoCure Ltd’s market cap?
NovoCure Ltd’s market cap is $1.42B.
When is NovoCure Ltd’s upcoming earnings report date?
NovoCure Ltd’s upcoming earnings report date is Apr 30, 2026 which is in 2 days.
How were NovoCure Ltd’s earnings last quarter?
NovoCure Ltd released its earnings results on Feb 26, 2026. The company reported -$0.22 earnings per share for the quarter, beating the consensus estimate of -$0.411 by $0.191.
Is NovoCure Ltd overvalued?
According to Wall Street analysts NovoCure Ltd’s price is currently Undervalued.
Does NovoCure Ltd pay dividends?
NovoCure Ltd does not currently pay dividends.
What is NovoCure Ltd’s EPS estimate?
NovoCure Ltd’s EPS estimate is -0.51.
How many shares outstanding does NovoCure Ltd have?
NovoCure Ltd has 113,794,395 shares outstanding.
What happened to NovoCure Ltd’s price movement after its last earnings report?
NovoCure Ltd reported an EPS of -$0.22 in its last earnings report, beating expectations of -$0.411. Following the earnings report the stock price went down -8.272%.
Which hedge fund is a major shareholder of NovoCure Ltd?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$27.40 (113.56% Upside)
$27.40 (113.56% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 86%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 55.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $595.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 2.2%
Last 30 Days ▲ 2.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.65%
12-Months-Change
Fundamentals
Return on Equity
-39.11%
Trailing 12-Months
Asset Growth
-35.18%
Trailing 12-Months
Company Description
NovoCure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
NVCR Company Deck
NVCR Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a mix of strong commercial and clinical progress (record revenue, meaningful active patient growth, FDA approval of Optune Pax, upcoming trial readouts, improved non‑GBM revenue trajectory, solid cash position and convertible note repayment) alongside near‑term profitability and operational challenges (net losses and negative adjusted EBITDA, gross margin compression, increased R&D spend, slower Optune Lua launch, reimbursement timing for Optune Pax, and a resolved Medicare administrative issue). Management provided formal 2026 guidance (revenue growth of 3%–8% and adjusted EBITDA of negative $20 million to breakeven), signifying a clear path toward stabilizing growth and driving to profitability while acknowledging near‑term execution and reimbursement risks.View all NVCR earnings summariesNVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$27.40
▲(113.56% Upside)
Technical Analysis
Ownership Overview
2.73% Insiders
21.85% Mutual Funds
0.08% Other Institutional Investors
60.27% Public Companies and
Individual Investors